Kyverna Therapeutics, Inc. (KYTX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Kyverna Therapeutics is a late-stage clinical immunology company focused on developing CAR T-cell therapies for neurologic autoimmune diseases. The lead product candidate, mivocabtagene autoleucel (miv-cel), is advancing through late-stage clinical development for Stiff Person Syndrome (SPS) and Generalized Myasthenia Gravis (gMG). The company is currently in a pre-revenue stage, having incurred losses since inception.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(38.3) million | $(78.0) million | $(86.7) million |
| Net Loss Per Share | $(0.63) | $(1.29) | $(2.01) |
| Operating Expenses | $39.6 million | $80.9 million | $91.8 million |
| Cash & Cash Equivalents | $31.8 million | $31.8 million | $124.1 million (Dec 31, 2025) |
| Marketable Securities | $167.6 million | $167.6 million | $155.2 million (Dec 31, 2025) |
| Total Liquidity | $199.4 million | $199.4 million | $279.3 million (Dec 31, 2025) |
| Term Loan Balance | $24.9 million | $24.9 million | $24.7 million (Dec 31, 2025) |
| Accumulated Deficit | $(502.9) million | $(502.9) million | $(424.8) million (Dec 31, 2025) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 10% year-over-year for the six months ended June 30, 2026, compared to the same period in 2025.
- Operating Expenses: Total operating expenses decreased by 12% ($10.9 million) year-over-year.
- R&D Expenses: Decreased by 25% ($18.4 million) primarily due to reduced Contract Manufacturing Organization (CMO) costs for BLA readiness and lower Clinical Research Organization (CRO) costs for the SPS trial.
- G&A Expenses: Increased by 40% ($7.5 million) driven by higher personnel costs, stock-based compensation, and professional services related to commercial preparation.
- Liquidity Position: Total cash and marketable securities decreased from $279.3 million at year-end 2025 to $199.4 million at June 30, 2026, reflecting a net cash burn of $92.3 million for the six-month period.
- Debt: The company drew $25.0 million under a Term A Loan facility in November 2025. Interest expense increased significantly due to this new debt obligation.
Guidance, Outlook, and Risks
- Regulatory Progress: The company initiated a rolling Biologics License Application (BLA) submission for miv-cel in SPS in Q2 2026, seeking priority review under the RMAT designation. The CMC module was submitted in July 2026, with full submission anticipated in Q4 2026.
- Clinical Updates: Positive 16-week data from the KYSA-8 Phase 2 trial in SPS was presented in April 2026. The company plans to report 12-month topline data in Q3 2026. Enrollment for the Phase 3 trial in gMG is expected to complete by mid-2027.
- Liquidity Outlook: Management estimates that existing cash, marketable securities, ATM proceeds, and available term loan capacity will fund operations for at least the next 12 months.
- Capital Markets: The company sold 426,038 shares under its ATM facility in Q2 2026 for net proceeds of $3.6 million. As of June 30, $96.3 million remains available under the ATM facility.
- Legal Contingencies: The company is a defendant in a shareholder class action lawsuit regarding its IPO registration statement. A motion to dismiss the second amended complaint is pending, with a hearing scheduled for September 3, 2026. No loss has been accrued as the outcome is uncertain.
- Risks: Key risks include the uncertainty of regulatory approval, the need for additional capital, reliance on third-party manufacturers, and potential litigation costs.
Investor Verification Checklist
- Verify the timeline and status of the rolling BLA submission for miv-cel in SPS and the anticipated FDA decision date.
- Confirm the remaining capacity and utilization rate of the $150 million Oxford Finance term loan facility.
- Monitor the outcome of the pending securities class action litigation and any potential financial impact.
- Review the 12-month topline data from the KYSA-8 SPS trial when released in Q3 2026.
- Assess the burn rate relative to the $199.4 million liquidity position to determine the runway for future financing needs.